| BIIB |
Report |
Q2 Total Revenue |
IN-LINE |
pred ~$2.460B vs. cons $2.456B |
MEDIUM |
| BIIB |
Report |
Q2 Non-GAAP Diluted EPS |
IN-LINE |
pred ~$2.90 vs. cons $2.876 |
MEDIUM |
| BIIB |
Report |
Q2 LEQEMBI Revenue |
BEAT |
pred ~$180M vs. cons $177.8M |
MEDIUM |
| BIIB |
Guide |
FY26 Total Revenue, Apellis-inclusive |
UNCHANGED |
guide ~$9.95B-$10.10B vs. cons $10.033B |
MEDIUM |
| BIIB |
Guide |
FY26 Non-GAAP Diluted EPS, Apellis-inclusive |
UNCHANGED |
guide ~$12.25-$13.00 vs. cons $12.599 |
MEDIUM |
| BIIB |
Guide |
FY26 commercial commentary |
UNCHANGED |
reiterate MS pressure and launch-product/Apellis growth bridge vs. UNVERIFIED consensus |
LOW |
| BIIB |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.5% |
— |
LOW |
| BIIB |
Return |
5-day cumulative residual |
-2.5% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — modest estimate pressure from an in-line package |
LOW |